Gregory J Riely

Oct 29, 2024 | onclive.com | Gregory J Riely |Benjamin Besse

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC. Clinicians referring a patient to MSK can do so by visiting msk.org/refer , emailing [email protected] , or by calling 833-315-2722

Oct 28, 2024 | onclive.com | Benjamin Besse |Gregory J Riely

Progression Patterns and Subsequent Therapies after Lorlatinib in ALK+ NSCLCGregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC. Clinicians referring a patient to MSK can do so by visiting msk.org/refer , emailing [email protected] , or by calling 833-315-2722

Oct 25, 2024 | onclive.com | Gregory J Riely |Benjamin Besse

Testing for ALK Fusions and ROS1 Rearrangements in NSCLCGregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer. Clinicians referring a patient to MSK can do so by visiting msk.org/refer , emailing [email protected] , or by calling 833-315-2722